MDNA News and Press, Medicenna Therapeutics Corp. From 05/20/21

TORONTO and HOUSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on May 28, 2021 at 8:30 AM ET to ...

Medicenna Therapeutics (MDNA) announces the appointment of Mann Muhsin as the company’s chief medical officer.Muhsin has more than 20 years of experience in medical practice and drug development, and has a track record of innovation in oncology and immuno-oncology trial ...

TORONTO and HOUSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Mann Muhsin, MD, as the Company’s Chief...

Medicenna Therapeutics ([[MDNA]] +2.3%) posted positive data from its Phase 2b trial testing its MDNA55 treatment in patients with recurrent glioblastoma ((rGBM)), the most common and uniformly fatal form of brain cancer.The results from the study were published in a peer-reviewed public...

-- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma -- Medicenna’s proposed patient population shows a tumor control rate of 81% (26/3...

Medicenna Therapeutics (MDNA) announces the appointment of Kevin Moulder as the company’s chief scientific officer.Moulder brings over 30 years of experience in drug discovery and development in the fields of protein design, antibody technology, immuno-oncology, inflamma...

TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Kevin Moulder, PhD, as the Company’s ...

TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,...

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages -- Data demonstrate the potential to overcome immunotherapy resistance mechanisms and treat immunologically “cold” tumo...

Potential for 100 gene therapy trials to be using ClearPoint. Expect significant growth in 2H 2021 as elective surgeries rebound and clinical trials restart. Recent expansion to Europe augurs well for European biologics partners. We see potential for $100M+ revenues and 30%+ n...